argenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in generalized myasthenia gravis at American Academy of Neurology (AAN) Annual Meeting

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Matthew Durham
Omnidynamic Marketing

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Paul Theisen
Patient Acquisition

Matt Turner
Patient Affordability

Liz Kane
Impactful Strategy

Suma Ramadas, PhD
Medical Affairs

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence

Daniel Sontupe
Market Access

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling